drugset / Trial / NCT00648921
Fasting Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study was to investigate the bioequivalence of Mylan's olanzapine 5 mg tablets to Eli Lilly's Zyprexa® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administered under fasting conditions.
Timeline
- Start
- 2003-06
- Primary completion
- 2003-07
- Completion
- 2003-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olanzapine | Small molecule | 5 mg | Oral |
Indications
No indication recorded.